시장보고서
상품코드
1299829

세계의 종양학용 인공지능(AI) 시장(2023-2033년)

Artificial Intelligence (AI) in Oncology Market Report 2023-2033

발행일: | 리서치사: Visiongain Reports Ltd. | 페이지 정보: 영문 289 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 종양학용 인공지능(AI) 시장 규모는 2033년까지 43.6%의 CAGR로 성장할 것으로 예측되고 있습니다. Drug Discovery의 가속화와 표적 치료의 확대는 시장의 성장을 촉진할 가능성이 있습니다.

세계의 종양학용 인공지능(AI) 시장에 대해 조사했으며, 시장 개요, 시장 분석, 기업 개요 등의 정보를 제공하고 있습니다.

목차

제1장 리포트의 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
  • 촉진요인
  • 억제요인
  • 시장 기회
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
    • 공급 기업의 교섭력
    • 구매자의 교섭력
    • 경쟁 기업간 경쟁 관계
    • 대체품의 위협
    • 신규 진출업체의 위협
  • PEST 분석

제4장 종양학용 인공지능(AI) 시장 분석 : 제품 유형별

  • 주요 조사 결과
  • 제품 유형 부문 : 시장 매력 지수
  • 종양학용 인공지능(AI) 시장 규모 추정과 예측 : 제품 유형별
  • 소프트웨어
  • 하드웨어
  • 서비스

제5장 종양학용 인공지능(AI) 시장 분석 : 사용 유형별

  • 주요 조사 결과
  • 사용 유형 부문 : 시장 매력 지수
  • 종양학용 인공지능(AI) 시장 규모 추정과 예측 : 사용 유형별
  • 암연구
  • 진단 전 스크리닝과 진단
  • 치료

제6장 종양학용 인공지능(AI) 시장 분석 : 최종사용자별

  • 주요 조사 결과
  • 최종사용자 부문 : 시장 매력 지수
  • 종양학용 인공지능(AI) 시장 규모 추정과 예측 : 최종사용자별
  • 제약기업 및 바이오의약품 기업
  • 연구기관
  • 병원과 진단 센터
  • 기타

제7장 종양학용 인공지능(AI) 시장 분석 : 질환 유형별

  • 주요 조사 결과
  • 질환 유형 부문 : 시장 매력 지수
  • 종양학용 인공지능(AI) 시장 규모 추정과 예측 : 질환 유형별
  • 폐암
  • 유방암
  • 전립선암
  • 결장암
  • 기타

제8장 종양학용 인공지능(AI) 시장 분석 : 지역별

  • 주요 조사 결과
  • 지역 시장 규모 추정과 예측

제9장 북미의 종양학용 인공지능(AI) 시장 분석

제10장 유럽의 종양학용 인공지능(AI) 시장 분석

제11장 아시아태평양의 종양학용 인공지능(AI) 시장 분석

제12장 라틴아메리카의 종양학용 인공지능(AI) 시장 분석

제13장 중동 및 아프리카의 종양학용 인공지능(AI) 시장 분석

제14장 기업 개요

  • 경쟁 구도(2022년)
  • 전략 전망
  • IBM Corporation
  • GE Healthcare
  • iCAD
  • Siemen's Healthineers
  • Google Health
  • Intel Corporation
  • NVIDIA
  • Azra AI
  • ConcertAI
  • Digital Diagnostics
  • CloudMedX Health
  • Enlitic
  • SkinVision
  • Therapixel
  • Botkin.AI
  • Owkin

제15장 결론과 권장사항

  • 결론
  • 시장 참여 기업에 대한 권장사항
KSA 23.07.07

The global Artificial Intelligence (AI) in Oncology market is projected to grow at a CAGR of 43.6% by 2033.

“The Artificial Intelligence (AI) in Oncology Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Accelerated Drug Discovery and Targeted Therapies Driving Market Growth

AI technologies are transforming the drug research and development process in cancer by harnessing massive volumes of data and smart algorithms. These developments seek to speed up the identification of prospective medication candidates, improve their efficacy, and make the development of targeted medicines easier. AI in drug development has the potential to dramatically reduce the time and expense associated with traditional techniques.

Collaborations between pharmaceutical corporations, technology businesses, and academic institutions have increased as a result of the development of AI-driven platforms and tools for drug discovery and development. These collaborations attempt to use AI to accelerate the development of new cancer medicines. For instance, in May 2023, the University of Sydney and the Australian business Pharos Therapeutics agreed to use AI to advance medication discovery for the treatment of cancer and uncommon disorders.

Lack of Standardization causes significant barriers

Standardized data collection and annotation practices are crucial in AI-driven oncology research and care. Variations in data collection methods, formats, and annotation protocols can impact the performance and generalizability of AI algorithms. By standardizing these processes, the quality and consistency of data can be improved, leading to more robust AI models. Standardization also facilitates data sharing, collaboration, and reproducibility, enabling meaningful comparisons and advancements in the field.

For instance, collaborative efforts between healthcare institutions and technology companies, such as the Cancer Imaging Archive (TCIA) and industry-led consortia like the Digital Imaging and Communications in Medicine (DICOM) are striving towards standardizing data sharing, storage, and annotation practices in oncology imaging. These initiatives promote the use of standardized guidelines and protocols for data collection, algorithm development, and evaluation.

By addressing the lack of standardization in AI oncology, stakeholders can overcome barriers to market growth. Collaborative initiatives, industry partnerships, and regulatory guidance are essential to establish comprehensive frameworks and guidelines for data collection, algorithm development, and evaluation. These efforts ensure that data collection methods, formats, and annotation protocols are consistent and harmonized across different healthcare institutions and research organizations.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the AI in oncology market evolving?
  • What is driving and restraining the AI in oncology market?
  • How will each AI in oncology submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each AI in oncology submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading AI in oncology markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the AI in oncology projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of AI in oncology projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the AI in oncology market?
  • Where is the AI in oncology market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the AI in oncology market today, and over the next 10 years:

  • Our 289-page report provides 123 tables and 163 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the AI in oncology market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising AI in oncology prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product Type

  • Software
  • Hardware
  • Services

Usage Type

  • Cancer Research
  • Pre-screening and Diagnosis
  • Treatment

Disease Type

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colon Cancer
  • Others

End-users

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Hospitals and Diagnostic Centres
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the AI in Oncology Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Azra AI
  • Botkin.AI
  • CloudMedX Health
  • ConcertAI
  • Digital Diagnostics AI
  • Enlitic
  • GE Healthcare
  • Google Health
  • IBM Corporation
  • iCAD
  • Intel Corporation
  • NVIDIA
  • Owkin
  • Siemen's Healthineers
  • SkinVision
  • Therapixel

Overall world revenue for AI in oncology market, 2023 to 2033 in terms of value the market will surpass US$2,617.6 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the AI in Oncology Market, 2023 to 2033 report help you?

In summary, our 280+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for AI in Oncology Market, 2023 to 2033 Market, with forecasts for product types, usage types, disease types and end-users types, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 20 key national markets - See forecasts for the AI in Oncology Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, South Korea, Singapore, Brazil, Mexico, Argentina, Colombia, GCC, South Africa, and among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the AI in Oncology Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the AI in oncology Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to AI in Oncology Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Early Detection and Diagnosis Fuelling the Growth of Ai in Oncology
      • 3.2.1.2 AI Technology Breakthroughs Improved Accuracy and Efficiency
      • 3.2.1.3 Generation of Large And Complex Healthcare Datasets In Driving The Market
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Security and Privacy of Data Concerns Causes Significant Barriers
      • 3.2.2.2 Lack Of Skilled AI Workforce and Cost And Infrastructure Requirement Pose Significant Challenges
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Rising Need Of Remote Monitoring And Telemedicine
      • 3.2.3.2 Increasing Demand For Personalised Medication Is Driving Market Expansion
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 AI in Oncology Market Analysis by Product Type

  • 4.1 Key Findings
  • 4.2 Product Type Segment: Market Attractiveness Index
  • 4.3 AI in Oncology Market Size Estimation and Forecast by Product Type
  • 4.4 Software
    • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Hardware
    • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.6 Services
    • 4.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.6.2 Market Share by Region, 2023 & 2033 (%)

5 AI in Oncology Market Analysis by Usage Type

  • 5.1 Key Findings
  • 5.2 Usage Type Segment: Market Attractiveness Index
  • 5.3 AI in Oncology Market Size Estimation and Forecast by Usage Type
  • 5.4 Cancer Research
    • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Pre-screening and Diagnosis
    • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Treatment
    • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 AI in Oncology Market Analysis by End-user

  • 6.1 Key Findings
  • 6.2 End-user Segment: Market Attractiveness Index
  • 6.3 AI in Oncology Market Size Estimation and Forecast by End-user
  • 6.4 Pharmaceutical and Biopharmaceutical Companies
    • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Research Institutes
    • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Hospitals and Diagnostic Centres
    • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)
  • 6.7 Others
    • 6.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.7.2 Market Share by Region, 2023 & 2033 (%)

7 AI in Oncology Market Analysis by Disease Type

  • 7.1 Key Findings
  • 7.2 Disease Type Segment: Market Attractiveness Index
  • 7.3 AI in Oncology Market Size Estimation and Forecast by Disease Type
  • 7.4 Lung Cancer
    • 7.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.4.2 Market Share by Region, 2023 & 2033 (%)
  • 7.5 Breast Cancer
    • 7.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.5.2 Market Share by Region, 2023 & 2033 (%)
  • 7.6 Prostate Cancer
    • 7.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.6.2 Market Share by Region, 2023 & 2033 (%)
  • 7.7 Colon Cancer
    • 7.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.7.2 Market Share by Region, 2023 & 2033 (%)
  • 7.8 Others
    • 7.8.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.8.2 Market Share by Region, 2023 & 2033 (%)

8 AI in Oncology Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America AI in Oncology Market Analysis

  • 9.1 Key Findings
  • 9.2 North America AI in Oncology Market Attractiveness Index
  • 9.3 North America AI in Oncology Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 North America AI in Oncology Market Size Estimation and Forecast by Country
  • 9.5 North America AI in Oncology Market Size Estimation and Forecast by Product Type
  • 9.6 North America AI in Oncology Market Size Estimation and Forecast by Usage Type
  • 9.7 North America AI in Oncology Market Size Estimation and Forecast by End-user
  • 9.8 North America AI in Oncology Market Size Estimation and Forecast by Disease Type
  • 9.9 U.S. AI in Oncology Market Analysis
  • 9.10 Canada AI in Oncology Market Analysis

10 Europe AI in Oncology Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe AI in Oncology Market Attractiveness Index
  • 10.3 Europe AI in Oncology Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Europe AI in Oncology Market Size Estimation and Forecast by Country
  • 10.5 Europe AI in Oncology Market Size Estimation and Forecast by Product Type
  • 10.6 Europe AI in Oncology Market Size Estimation and Forecast by Usage Type
  • 10.7 Europe AI in Oncology Market Size Estimation and Forecast by End-user
  • 10.8 Europe AI in Oncology Market Size Estimation and Forecast by Disease Type
  • 10.9 Germany AI in Oncology Market Analysis
  • 10.10 France AI in Oncology Market Analysis
  • 10.11 UK AI in Oncology Market Analysis
  • 10.12 Italy AI in Oncology Market Analysis
  • 10.13 Spain AI in Oncology Market Analysis
  • 10.14 Russia AI in Oncology Market Analysis
  • 10.15 Rest of Europe AI in Oncology Market Analysis

11 Asia Pacific AI in Oncology Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific AI in Oncology Market Attractiveness Index
  • 11.3 Asia Pacific AI in Oncology Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 Asia Pacific AI in Oncology Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific AI in Oncology Market Size Estimation and Forecast by Product Type
  • 11.6 Asia Pacific AI in Oncology Market Size Estimation and Forecast by Usage Type
  • 11.7 Asia Pacific AI in Oncology Market Size Estimation and Forecast by End-user
  • 11.8 Asia Pacific AI in Oncology Market Size Estimation and Forecast by Disease Type
  • 11.9 Japan AI in Oncology Market Analysis
  • 11.10 China AI in Oncology Market Analysis
  • 11.11 India AI in Oncology Market Analysis
  • 11.12 Australia AI in Oncology Market Analysis
  • 11.13 South Korea AI in Oncology Market Analysis
  • 11.14 Singapore AI in Oncology Market Analysis
  • 11.15 Rest of Asia Pacific AI in Oncology Market Analysis

12 Latin America AI in Oncology Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America AI in Oncology Market Attractiveness Index
  • 12.3 Latin America AI in Oncology Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 12.4 Latin America AI in Oncology Market Size Estimation and Forecast by Country
  • 12.5 Latin America AI in Oncology Market Size Estimation and Forecast by Product Type
  • 12.6 Latin America AI in Oncology Market Size Estimation and Forecast by Usage Type
  • 12.7 Latin America AI in Oncology Market Size Estimation and Forecast by End-user
  • 12.8 Latin America AI in Oncology Market Size Estimation and Forecast by Disease Type
  • 12.9 Brazil AI in Oncology Market Analysis
  • 12.10 Mexico AI in Oncology Market Analysis
  • 12.11 Argentina AI in Oncology Market Analysis
  • 12.12 Colombia AI in Oncology Market Analysis
  • 12.13 Rest of Latin America AI in Oncology Market Analysis

13 MEA AI in Oncology Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA AI in Oncology Market Attractiveness Index
  • 13.3 MEA AI in Oncology Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 13.4 MEA AI in Oncology Market Size Estimation and Forecast by Country
  • 13.5 MEA AI in Oncology Market Size Estimation and Forecast by Product Type
  • 13.6 MEA AI in Oncology Market Size Estimation and Forecast by Usage Type
  • 13.7 MEA AI in Oncology Market Size Estimation and Forecast by End-user
  • 13.8 MEA AI in Oncology Market Size Estimation and Forecast by Disease Type
  • 13.9 GCC AI in Oncology Market Analysis
  • 13.10 South Africa AI in Oncology Market Analysis
  • 13.11 Rest of MEA AI in Oncology Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2022
  • 14.2 Strategic Outlook
  • 14.3 IBM Corporation
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 GE Healthcare
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2019-2022
      • 14.4.3.2 R&D, 2019-2022
      • 14.4.3.3 Regional Market Shares, 2022
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 iCAD
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Siemen's Healthineers
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2018-2022
      • 14.6.3.2 R&D, 2018-2022
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Google Health
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2017-2022
      • 14.7.3.2 R&D, 2017-2022
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Intel Corporation
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2017-2022
      • 14.8.3.2 R&D, 2017-2022
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 NVIDIA
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2017-2022
      • 14.9.3.2 R&D, 2017-2022
      • 14.9.3.3 Regional Market Shares, 2022
    • 14.9.4 Product Benchmarking
    • 14.9.5 Service Benchmarking
    • 14.9.6 Strategic Outlook
  • 14.10 Azra AI
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Product Benchmarking
    • 14.10.4 Strategic Outlook
  • 14.11 ConcertAI
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 Service Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Digital Diagnostics
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Product Benchmarking
    • 14.12.4 Strategic Outlook
  • 14.13 CloudMedX Health
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
    • 14.13.4 Strategic Outlook
  • 14.14 Enlitic
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Service Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 SkinVision
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Product Benchmarking
    • 14.15.4 Strategic Outlook
  • 14.16 Therapixel
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Product Benchmarking
    • 14.16.4 Strategic Outlook
  • 14.17 Botkin.AI
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
    • 14.17.4 Strategic Outlook
  • 14.18 Owkin
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Product Benchmarking
    • 14.18.4 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from
  • 15.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제